Evidence map›Paper›PMID 36928295›Full record

ArticleEuropean heart journal2023

Lnc-ing epicardium-derived cells to cardiac remodelling: lncRNA-TARID as a novel antifibrotic option.

Xuekun Wu, Francesca Vacante, Joseph C Wu

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Xuekun WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-5429-3126
Francesca VacanteStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-5702-7253
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-6068-8041

Funding

Elucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCsR01HL130020 · NHLBI · STANFORD UNIVERSITY · PI Ronglih Liao, MARK MERCOLA · 2016 to 2026
$7.3M
Genome Editing of Human iPSCs to Study Inherited Hypertrophic CardiomyopathyR01HL126527 · NHLBI · STANFORD UNIVERSITY · PI QI, LEI STANLEY, WU, JOSEPH C. · 2015 to 2022
$5.4M
Human iPSC Model to Elucidate Metabolic Interplay in Diabetic CardimyopathyR01HL146690 · NHLBI · STANFORD UNIVERSITY · PI LIAO, RONGLIH, MERCOLA, MARK · 2019 to 2025
$5.1M
Elucidating Anthracycline-Induced Cell Type-Specific Cardiovascular Toxicity with CRISPRi/a ScreensR01HL150693 · NHLBI · STANFORD UNIVERSITY · PI Ronglih Liao, Joseph C. Wu · 2021 to 2026
$4.1M
NHLBI NIH HHS R01 HL130020NHLBI NIH HHS R01 HL146690NHLBI NIH HHS R01 HL150693NIH HHS R01 HL126527
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

RNA, AntisenseRNA, Long NoncodingBasic Helix-Loop-Helix ProteinsDemethylationHumansPericardiumVentricular RemodelingBasic Helix-Loop-Helix ProteinsRNA, AntisenseRNA, Long NoncodingTCF21 protein, human

Identifiers

PMID36928295
PMCPMC10182884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.